Anti-Cancer Activity, DFT and molecular docking study of new BisThiazolidine amide

Haider A. Omran, Ahmed A. Majed (Corresponding author), Kawkab Hussein, Dawood S. Abid, Mostafa A. Abdel-Maksoud, Ahmed Elwahsh, Mohamed Aufy (Corresponding author), Mohamed H. Kotob (Corresponding author)

Publications: Contribution to journalArticlePeer Reviewed

Abstract

In this study, a series of bis amide thiazolidine derivatives (Q1-Q6) were synthesized and their anticancer activity was evaluated against prostate (PC3) and breast (MCF7) cancer cells and normal cells line activity was evaluated against breast (MCF10), prostate (PNT1A) and living human cells (HUVEC) cancer cells. The thiazolidine rings were built from penicillamine and aromatic aldehydes (A1-A6), then converted to acetyl thiazolidines (B1-B6) using acetic anhydride, and finally linked with phenylene diamine to form the final compounds (Q1-Q6). Notably, compounds Q1 and Q3 displayed the highest activity against PC3, with IC50 values of 81 and 89 µg/ml, respectively. Docking simulations were performed for Q1, Q4, and Q5 against protein structures related to cancer (2FVD and 1SJ0). Additionally, DFT calculations were used to determine various molecular properties like HOMO/LUMO energies, band gap, and other descriptors, providing insights into the compounds’ stability and reactivity.

Original languageEnglish
Article number101835
JournalResults in Chemistry
Volume12
DOIs
Publication statusPublished - Dec 2024

Austrian Fields of Science 2012

  • 104004 Chemical biology

Keywords

  • Bisthiazolidine Amide. Anticancer. Molecular Docking. DFT

Fingerprint

Dive into the research topics of 'Anti-Cancer Activity, DFT and molecular docking study of new BisThiazolidine amide'. Together they form a unique fingerprint.

Cite this